Hub : Traits :

Number of treatments/medications taken

220 significantly associated models · 44 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 109126153 110517617 2 1 7.5e-08 1.5e-07 4.4e-01 98 SORT1
2 2 26624843 28038799 1 1 2.5e-07 3.7e-06 8.5e-05 28 CGREF1
3 3 48702606 50932324 14 1 8.5e-12 2.6e-11 2.6e-01 97 MST1R
4 4 102868793 104627833 6 1 1.5e-10 9.8e-10 1.0e+00 100 CISD2
5 5 113846922 115239004 1 1 2.8e-07 5.4e-06 2.8e-03 57 CTC-428G20.3
6 7 73425238 74494207 2 1 2.7e-08 1.2e-06 1.2e-01 90 PMS2P5
7 10 21123825 22724472 1 1 5.8e-08 1.6e-07 2.7e-01 96 MLLT10
8 10 133048749 134466163 1 1 1.4e-07 8.5e-07 8.4e-02 88 PPP2R2D
9 11 100168289 101559718 1 1 1.7e-07 1.1e-06 2.4e-02 78 TMEM133
10 12 111154626 113517494 3 1 1.1e-09 1.7e-14 1.2e-06 60 SH2B3
11 14 74424938 76089054 4 1 3.7e-11 6.1e-11 3.3e-01 98 RPS6KL1
12 15 80743350 81292020 1 1 1.1e-10 1.6e-09 5.0e-01 99 FAM108C1
13 15 91181489 91686147 1 1 1.5e-07 5.0e-05 6.0e-01 98 FES
14 17 47119135 47685050 1 1 3.3e-08 3.0e-11 1.3e-06 47 ZNF652
15 17 65431947 66828158 1 1 2.2e-07 5.1e-07 6.1e-01 99 SH3GL1P3
16 20 57525478 58079512 1 1 2.2e-08 4.6e-09 5.6e-03 78 ZNF831

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder or Schizophrenia 2.38 1 1 2.2 0.00 1.0e+00 FES
Depressed Affect (Nagel 2018) 3.60 3 2 4.4 0.00 1.0e+00 MST1R RPS6KL1 SH2B3
Intelligence (Savage-Jansen 2018) 3.77 2 1 2.2 0.00 1.0e+00 MST1R PPP2R2D
Neuroticism (Nagel 2018) 2.87 1 1 2.2 0.00 1.0e+00 RPS6KL1
Schizophrenia (2018) 2.59 1 1 2.2 0.00 1.0e+00 FES
Worry (Nagel 2018) 2.51 1 1 2.2 0.00 1.0e+00 RPS6KL1
Crohns Disease (2017) 2.58 1 1 2.2 0.00 1.0e+00 MST1R
Irritable Bowel Disease (IBD) 3.73 2 1 2.2 0.00 1.0e+00 MST1R PMS2P5
Ulcerative Colitis (UC) 3.58 1 1 2.2 0.00 1.0e+00 MST1R
Major Depression (MDD) 2.12 1 0 0.0 0.00 1.0e+00 RPS6KL1
Reaction Time 3.02 1 1 2.2 0.00 1.0e+00 SH2B3
Verbal and Numeric Reasoning (VNR) 2.78 1 1 2.2 0.00 1.0e+00 MST1R
Breast Cancer 3.28 2 2 4.4 0.00 1.0e+00 FES MLLT10
Ovarian Cancer 3.12 1 1 2.2 0.00 1.0e+00 MLLT10
Age at First Birth 4.80 2 1 2.2 0.00 1.0e+00 MST1R ZNF652
Coronary Artery Disease (CAD) 3.90 2 0 0.0 0.00 1.0e+00 MST1R SH2B3
Crohns Disease (2012) 2.76 1 1 2.2 0.00 1.0e+00 MST1R
Fasting Glucose 3.88 1 1 2.2 0.00 1.0e+00 CGREF1
HDL Cholesterol 2.82 1 1 2.2 0.00 1.0e+00 SORT1
LDL Cholesterol 33.13 2 1 2.2 0.00 1.0e+00 SH2B3 SORT1
Neuroticism (2016) 2.06 1 0 0.0 0.00 1.0e+00 RPS6KL1
Primary Biliary Cirrhosis 2.94 2 1 2.2 0.00 1.0e+00 CISD2 SH2B3
Rheumatoid Arthritis 2.21 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia (2014) 2.68 2 1 2.2 0.00 1.0e+00 CISD2 FES
Triglycerides 6.70 2 1 2.2 0.00 1.0e+00 CGREF1 SH3GL1P3
Type 2 Diabetes (T2D) (2012) 2.45 1 0 0.0 0.00 1.0e+00 CISD2
Ulcerative Colitis 2.91 1 1 2.2 0.00 1.0e+00 MST1R
Blood Eosinophil Count 14.56 5 4 8.9 0.76 1.3e-01 MST1R SH2B3 SH3GL1P3 ZNF652 ZNF831
Blood Platelet Count 3.35 3 3 6.7 0.00 1.0e+00 CGREF1 RPS6KL1 SH2B3
Blood Red Count 2.12 3 1 2.2 0.00 1.0e+00 PMS2P5 SH2B3 TMEM133
Blood White Count 6.94 5 4 8.9 0.89 4.1e-02 CGREF1 FES MST1R SH2B3 ZNF652
Heel T-Score 1.37 6 1 2.2 0.16 7.6e-01 MST1R PMS2P5 RPS6KL1 SH3GL1P3 SORT1 TMEM133
BMI 5.75 8 5 11.1 0.92 1.3e-03 CISD2 CTC-428G20.3 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3 ZNF652
Height 1.75 9 8 17.8 -0.49 1.8e-01 CGREF1 FES PPP2R2D RPS6KL1 SH2B3 SH3GL1P3 SORT1 ZNF652 ZNF831
Systolic Blood Pressure 12.66 12 8 17.8 0.73 7.1e-03 CGREF1 FAM108C1 FES MLLT10 PMS2P5 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3 TMEM133 ZNF652 ZNF831
Smoking Status 3.23 3 1 2.2 0.00 1.0e+00 FAM108C1 MLLT10 ZNF652
Allergy or Eczema 2.49 3 1 2.2 0.00 1.0e+00 CISD2 SH2B3 ZNF652
Cardiovascular Disease 15.76 11 9 20.0 0.94 2.1e-05 CGREF1 CISD2 FAM108C1 FES MLLT10 PMS2P5 SH2B3 SORT1 TMEM133 ZNF652 ZNF831
Hypothyroidism (self reported) 7.85 2 1 2.2 0.00 1.0e+00 RPS6KL1 SH2B3
Respiratory disease 3.13 2 1 2.2 0.00 1.0e+00 MST1R ZNF652
Type 2 Diabetes (T2D) (2018) 2.75 2 0 0.0 0.00 1.0e+00 MST1R SH2B3
Lung FEV1/FVC ratio 3.35 6 4 8.9 -0.04 9.4e-01 MLLT10 RPS6KL1 SH3GL1P3 SORT1 TMEM133 ZNF652
Lung FVC 1.88 5 1 2.2 -0.71 1.8e-01 MLLT10 MST1R SH2B3 SH3GL1P3 TMEM133
Neuroticism 3.75 2 1 2.2 0.00 1.0e+00 MST1R RPS6KL1
Hair Pigment 0.64 5 3 6.7 0.14 8.2e-01 CGREF1 FES SH2B3 SH3GL1P3 ZNF831
Tanning 0.39 2 0 0.0 0.00 1.0e+00 RPS6KL1 SH2B3
Hand grip strength (left) 2.31 3 0 0.0 0.00 1.0e+00 MLLT10 RPS6KL1 SH3GL1P3
Sensitivity / hurt feelings 1.93 1 0 0.0 0.00 1.0e+00 FES
Relative age of first facial hair 1.36 1 0 0.0 0.00 1.0e+00 PMS2P5
Other serious medical condition/disability diagnosed by doctor 3.12 1 0 0.0 0.00 1.0e+00 PMS2P5
Ever used hormone-replacement therapy (HRT) 2.10 1 0 0.0 0.00 1.0e+00 SH3GL1P3
Ever had hysterectomy (womb removed) 2.82 1 0 0.0 0.00 1.0e+00 MLLT10
Systolic blood pressure, automated reading 9.80 7 5 11.1 0.90 5.2e-03 FAM108C1 FES PMS2P5 RPS6KL1 SH2B3 TMEM133 ZNF831
Angina 7.95 3 3 6.7 0.00 1.0e+00 FES SORT1 ZNF652
Medication: Co-codamol 2.51 1 0 0.0 0.00 1.0e+00 MST1R
Medication: Metformin 2.85 1 0 0.0 0.00 1.0e+00 CISD2
Impedance of leg (right) 3.37 6 3 6.7 -0.45 3.7e-01 FAM108C1 FES MST1R PMS2P5 RPS6KL1 ZNF652
Leg fat-free mass (left) 3.23 7 2 4.4 0.57 1.9e-01 CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 SH3GL1P3
Trunk fat percentage 5.16 6 3 6.7 0.94 5.0e-03 FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Hand grip strength (right) 1.95 2 0 0.0 0.00 1.0e+00 MLLT10 SH3GL1P3
Current tobacco smoking 2.60 1 0 0.0 0.00 1.0e+00 SH3GL1P3
Maternal smoking around birth 3.01 2 0 0.0 0.00 1.0e+00 MLLT10 MST1R
Fed-up feelings 4.84 3 3 6.7 0.00 1.0e+00 MST1R RPS6KL1 SH2B3
Relative age voice broke 1.66 1 0 0.0 0.00 1.0e+00 PMS2P5
Taking other prescription medications 11.39 8 4 8.9 0.99 3.8e-06 CISD2 MLLT10 MST1R PMS2P5 RPS6KL1 SH2B3 SH3GL1P3 ZNF652
Age when periods started (menarche) 2.67 3 1 2.2 0.00 1.0e+00 FAM108C1 MST1R PMS2P5
Bilateral oophorectomy (both ovaries removed) 2.92 1 0 0.0 0.00 1.0e+00 MLLT10
Heel bone mineral density (BMD) T-score, automated (left) 1.52 1 0 0.0 0.00 1.0e+00 MST1R
Qualifications: CSEs or equivalent 2.18 1 0 0.0 0.00 1.0e+00 MST1R
High blood pressure 13.91 11 7 15.6 0.94 2.0e-05 CGREF1 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 PMS2P5 SH2B3 TMEM133 ZNF652 ZNF831
Hayfever, allergic rhinitis or eczema 2.10 1 1 2.2 0.00 1.0e+00 ZNF652
Medication: Atenolol 7.57 3 2 4.4 0.00 1.0e+00 FES SH2B3 TMEM133
Medication: Levothyroxine sodium 6.57 1 1 2.2 0.00 1.0e+00 SH2B3
Sitting height 1.34 5 1 2.2 0.58 3.0e-01 CGREF1 MLLT10 PPP2R2D ZNF652 ZNF831
High blood pressure (mother) 6.47 3 1 2.2 0.00 1.0e+00 CGREF1 FES ZNF831
Body mass index (BMI) 6.02 5 5 11.1 0.97 7.0e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Impedance of leg (left) 3.45 6 3 6.7 -0.43 3.9e-01 FAM108C1 FES MST1R PMS2P5 RPS6KL1 ZNF652
Leg predicted mass (left) 3.24 8 2 4.4 0.47 2.4e-01 CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 PPP2R2D SH2B3 SH3GL1P3
Trunk fat mass 5.31 5 4 8.9 0.98 2.5e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Waist circumference 5.78 5 5 11.1 0.98 3.5e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Past tobacco smoking 3.33 4 0 0.0 -0.99 9.2e-03 MLLT10 RPS6KL1 SH2B3 ZNF652
Nervous feelings 1.84 1 1 2.2 0.00 1.0e+00 RPS6KL1
Frequency of tenseness / restlessness in last 2 weeks 2.59 1 0 0.0 0.00 1.0e+00 MST1R
Forced vital capacity (FVC) 1.62 4 0 0.0 -1.00 1.2e-03 MLLT10 MST1R PPP2R2D TMEM133
Heel bone mineral density (BMD) T-score, automated (right) 1.39 1 0 0.0 0.00 1.0e+00 MST1R
Ever unenthusiastic/disinterested for a whole week 2.85 1 0 0.0 0.00 1.0e+00 RPS6KL1
Qualifications: None of the above 3.82 2 2 4.4 0.00 1.0e+00 MST1R PPP2R2D
Heart attack 6.76 5 1 2.2 0.99 1.2e-03 FES SH2B3 SORT1 ZNF652 ZNF831
Allergy 2.99 1 1 2.2 0.00 1.0e+00 ZNF652
Diabetes (self-reported) 3.03 2 0 0.0 0.00 1.0e+00 MST1R PMS2P5
Medication: Ramipril 6.29 3 0 0.0 0.00 1.0e+00 CISD2 FES TMEM133
Medication: Simvastatin 11.15 3 1 2.2 0.00 1.0e+00 FES SORT1 ZNF831
Fluid intelligence score 2.76 1 1 2.2 0.00 1.0e+00 MST1R
Illnesses of siblings 6.24 3 0 0.0 0.00 1.0e+00 FES SH2B3 TMEM133
Neuroticism score 3.37 2 1 2.2 0.00 1.0e+00 MST1R RPS6KL1
Weight 4.80 6 5 11.1 0.76 7.8e-02 FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 SH3GL1P3
Impedance of arm (right) 4.17 8 3 6.7 -0.64 8.9e-02 CGREF1 CISD2 FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 ZNF652
Arm fat percentage (right) 5.00 6 4 8.9 0.94 4.7e-03 FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Trunk fat-free mass 2.93 6 3 6.7 -0.24 6.5e-01 CGREF1 FAM108C1 MST1R RPS6KL1 SH2B3 SORT1
Hip circumference 3.99 6 4 8.9 0.74 9.0e-02 FAM108C1 MLLT10 MST1R PMS2P5 SH2B3 SH3GL1P3
Alcohol intake versus 10 years previously 3.17 1 1 2.2 0.00 1.0e+00 MST1R
Father's age at death 5.03 4 1 2.2 -0.98 1.7e-02 FES MST1R SH2B3 SORT1
Worrier / anxious feelings 2.20 1 1 2.2 0.00 1.0e+00 RPS6KL1
Number of live births 2.49 2 0 0.0 0.00 1.0e+00 CISD2 MST1R
Forced expiratory volume in 1-second (FEV1) 1.79 3 0 0.0 0.00 1.0e+00 MST1R PPP2R2D TMEM133
Qualifications: A levels/AS levels or equivalent 5.43 2 1 2.2 0.00 1.0e+00 MST1R PPP2R2D
Mouth/teeth dental problems: Dentures 2.01 1 1 2.2 0.00 1.0e+00 MST1R
Asthma 3.66 3 1 2.2 0.00 1.0e+00 MLLT10 MST1R ZNF652
Medication: Cholesterol lowering 14.53 5 2 4.4 0.16 7.9e-01 CGREF1 FES SORT1 TMEM133 ZNF831
Prospective memory result 2.61 1 0 0.0 0.00 1.0e+00 MST1R
Illnesses of mother 5.66 1 1 2.2 0.00 1.0e+00 FES
Forced expiratory volume in 1-second (FEV1), Best measure 1.59 3 0 0.0 0.00 1.0e+00 MST1R PPP2R2D TMEM133
Impedance of arm (left) 4.40 7 3 6.7 -0.60 1.6e-01 CGREF1 CISD2 FAM108C1 MLLT10 MST1R SH2B3 ZNF652
Arm fat mass (right) 5.47 5 5 11.1 0.99 1.9e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Trunk predicted mass 2.89 6 3 6.7 -0.24 6.4e-01 CGREF1 FAM108C1 MST1R RPS6KL1 SH2B3 SORT1
Standing height 1.78 8 6 13.3 -0.52 1.9e-01 CGREF1 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3 SORT1 ZNF652 ZNF831
Exposure to tobacco smoke at home 2.20 1 0 0.0 0.00 1.0e+00 MST1R
Tense / 'highly strung' 1.79 1 0 0.0 0.00 1.0e+00 RPS6KL1
Seen doctor (GP) for nerves, anxiety, tension or depression 2.43 1 0 0.0 0.00 1.0e+00 RPS6KL1
Birth weight of first child 4.54 2 2 4.4 0.00 1.0e+00 FES SH2B3
Peak expiratory flow (PEF) 1.24 1 0 0.0 0.00 1.0e+00 MLLT10
Ever highly irritable/argumentative for 2 days 3.26 1 1 2.2 0.00 1.0e+00 MST1R
Qualifications: O levels/GCSEs or equivalent 2.83 2 0 0.0 0.00 1.0e+00 MST1R PPP2R2D
Blood clot in the leg (DVT) 2.11 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Paracetamol 4.12 2 0 0.0 0.00 1.0e+00 CGREF1 MLLT10
Medication for cholesterol, blood pressure or diabetes 13.93 9 5 11.1 -0.96 2.8e-05 CISD2 FAM108C1 FES MST1R SH2B3 SORT1 TMEM133 ZNF652 ZNF831
Gout (self-reported) 3.55 2 1 2.2 0.00 1.0e+00 CGREF1 SH2B3
Hypothyroidism/myxoedema (self-reported) 6.58 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Amlodipine 6.88 3 2 4.4 0.00 1.0e+00 FAM108C1 FES TMEM133
Medication: Ventolin 100micrograms inhaler 3.11 2 0 0.0 0.00 1.0e+00 MST1R ZNF652
Birth weight 2.90 2 2 4.4 0.00 1.0e+00 FES SH2B3
Chronic bronchitis/emphysema (mother) 2.65 1 0 0.0 0.00 1.0e+00 MST1R
High blood pressure (siblings) 6.89 4 0 0.0 1.00 4.3e-03 CGREF1 FES SH2B3 TMEM133
Forced vital capacity (FVC), Best measure 1.52 2 1 2.2 0.00 1.0e+00 MLLT10 MST1R
Body fat percentage 5.75 6 3 6.7 0.95 3.9e-03 FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Leg fat percentage (right) 6.60 6 4 8.9 0.94 4.7e-03 FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Arm fat-free mass (right) 3.51 7 2 4.4 0.27 5.5e-01 CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Exposure to tobacco smoke outside home 2.60 1 0 0.0 0.00 1.0e+00 MST1R
Comparative body size at age 10 1.60 1 1 2.2 0.00 1.0e+00 ZNF652
Wheeze or whistling in the chest in last year 4.80 4 1 2.2 0.96 3.7e-02 MST1R RPS6KL1 SH3GL1P3 ZNF652
Age at first live birth 4.35 1 1 2.2 0.00 1.0e+00 MST1R
Health satisfaction 3.64 2 0 0.0 0.00 1.0e+00 MST1R SH3GL1P3
Qualifications: College or University degree 5.18 3 2 4.4 0.00 1.0e+00 MLLT10 MST1R PPP2R2D
Medication for pain relief, constipation, heartburn 7.24 6 2 4.4 -0.99 7.6e-05 CGREF1 CISD2 FAM108C1 MLLT10 RPS6KL1 SH3GL1P3
Medication: Blood pressure 12.52 7 7 15.6 0.98 1.6e-04 CISD2 FAM108C1 FES SH2B3 TMEM133 ZNF652 ZNF831
Angina (self-reported) 7.75 3 2 4.4 0.00 1.0e+00 FES SORT1 ZNF652
Medication: Allopurinol 2.71 2 0 0.0 0.00 1.0e+00 CGREF1 SH2B3
Medication: Omeprazole 3.59 1 0 0.0 0.00 1.0e+00 MST1R
Medication: Seretide 50 evohaler 3.13 2 0 0.0 0.00 1.0e+00 MST1R ZNF652
Mean time to correctly identify matches 3.90 1 1 2.2 0.00 1.0e+00 SH2B3
Whole body fat mass 5.82 5 4 8.9 0.99 2.1e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Leg fat mass (right) 6.50 5 5 11.1 0.98 4.2e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Arm predicted mass (right) 3.64 7 3 6.7 0.30 5.2e-01 CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Pulse rate, automated reading 2.16 4 0 0.0 1.00 1.8e-04 CGREF1 MST1R PMS2P5 SORT1
Alcohol intake frequency. 4.42 3 3 6.7 0.00 1.0e+00 CGREF1 MST1R PMS2P5
Comparative height size at age 10 2.51 8 1 2.2 -0.31 4.5e-01 CGREF1 FAM108C1 FES PMS2P5 RPS6KL1 SH2B3 SH3GL1P3 SORT1
Suffer from 'nerves' 1.61 1 0 0.0 0.00 1.0e+00 RPS6KL1
Overall health rating 7.83 8 3 6.7 0.97 3.8e-05 CISD2 CTC-428G20.3 MLLT10 MST1R PMS2P5 PPP2R2D SH3GL1P3 ZNF652
Had major operations 2.51 1 0 0.0 0.00 1.0e+00 ZNF652
Age at last live birth 4.69 2 1 2.2 0.00 1.0e+00 MST1R SH3GL1P3
Leg pain on walking 3.55 1 1 2.2 0.00 1.0e+00 MST1R
Qualifications: NVQ or HND or HNC or equivalent 2.59 1 0 0.0 0.00 1.0e+00 MST1R
Medication: Aspirin 6.99 3 2 4.4 0.00 1.0e+00 FES SH2B3 SORT1
Knee pain experienced in last month 3.04 2 0 0.0 0.00 1.0e+00 CTC-428G20.3 MST1R
Hypertension (Self-reported) 13.67 11 7 15.6 0.94 2.2e-05 CGREF1 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 PMS2P5 SH2B3 TMEM133 ZNF652 ZNF831
Illnesses of father: Heart disease 5.78 3 2 4.4 0.00 1.0e+00 FES SH2B3 SORT1
Smoking status: Previous 3.23 2 0 0.0 0.00 1.0e+00 MLLT10 SH2B3
Whole body fat-free mass 3.14 7 2 4.4 -0.04 9.3e-01 CGREF1 FAM108C1 MST1R RPS6KL1 SH2B3 SH3GL1P3 SORT1
Leg fat-free mass (right) 3.05 9 2 4.4 0.25 5.2e-01 CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3
Arm fat percentage (left) 5.10 6 4 8.9 0.94 5.9e-03 FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Mood swings 3.52 2 2 4.4 0.00 1.0e+00 MST1R RPS6KL1
Loneliness, isolation 3.58 3 0 0.0 0.00 1.0e+00 MST1R SH2B3 SH3GL1P3
Long-standing illness, disability or infirmity 5.86 4 0 0.0 1.00 1.3e-04 CTC-428G20.3 PMS2P5 SH3GL1P3 ZNF652
Ever had bowel cancer screening 2.27 2 0 0.0 0.00 1.0e+00 MLLT10 MST1R
Diabetes diagnosed by doctor 2.98 1 0 0.0 0.00 1.0e+00 MST1R
Qualifications: nursing, teaching 2.56 1 0 0.0 0.00 1.0e+00 MST1R
Mouth/teeth dental problems: Mouth ulcers 1.31 1 0 0.0 0.00 1.0e+00 SH2B3
Medication for cholesterol 10.26 9 3 6.7 -0.99 1.1e-06 CGREF1 CISD2 FAM108C1 FES RPS6KL1 SH2B3 SORT1 TMEM133 ZNF831
Medication: Laxatives (e.g. Dulcolax, Senokot) 2.29 1 0 0.0 0.00 1.0e+00 CGREF1
Breast cancer (self-reported) 1.63 1 0 0.0 0.00 1.0e+00 MLLT10
Asthma (self-reported) 3.58 2 1 2.2 0.00 1.0e+00 MST1R ZNF652
Osteoarthritis (self-reported) 2.31 1 0 0.0 0.00 1.0e+00 MST1R
Medication: Aspirin 6.86 2 2 4.4 0.00 1.0e+00 FES SORT1
Illnesses of father: None of the above (group 1) 5.54 2 1 2.2 0.00 1.0e+00 FES SH2B3
Smoking status: Current 2.63 1 0 0.0 0.00 1.0e+00 SH3GL1P3
Whole body water mass 3.17 8 2 4.4 0.08 8.6e-01 CGREF1 FAM108C1 MLLT10 MST1R RPS6KL1 SH2B3 SH3GL1P3 SORT1
Leg predicted mass (right) 3.06 9 2 4.4 0.24 5.3e-01 CGREF1 FAM108C1 MLLT10 MST1R PMS2P5 PPP2R2D RPS6KL1 SH2B3 SH3GL1P3
Arm fat mass (left) 5.49 5 5 11.1 0.98 2.5e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Number of self-reported non-cancer illnesses 11.19 8 5 11.1 0.98 1.6e-05 CGREF1 CISD2 MLLT10 PMS2P5 RPS6KL1 SH2B3 ZNF652 ZNF831
Miserableness 2.71 1 1 2.2 0.00 1.0e+00 MST1R
Guilty feelings 2.67 1 1 2.2 0.00 1.0e+00 RPS6KL1
Mother's age at death 2.53 1 0 0.0 0.00 1.0e+00 PMS2P5
Financial situation satisfaction 2.09 1 0 0.0 0.00 1.0e+00 MST1R
Medication: Blood pressure 11.13 8 5 11.1 0.96 1.7e-04 CISD2 FAM108C1 FES RPS6KL1 SH2B3 TMEM133 ZNF652 ZNF831
High cholesterol (Self-reported) 15.50 3 2 4.4 0.00 1.0e+00 CGREF1 SORT1 TMEM133
Medication: Bendroflumethiazide 6.36 5 0 0.0 0.99 4.6e-04 CISD2 FAM108C1 FES SH2B3 ZNF831
Medication: Paracetamol 4.43 2 0 0.0 0.00 1.0e+00 CGREF1 MLLT10
Medication: Lisinopril 4.29 2 0 0.0 0.00 1.0e+00 SH2B3 ZNF831
Medication: Atorvastatin 9.82 2 1 2.2 0.00 1.0e+00 CGREF1 SORT1
Illnesses of father: High blood pressure 5.65 2 1 2.2 0.00 1.0e+00 FES SH2B3
Ever smoked 2.58 3 0 0.0 0.00 1.0e+00 FES SH2B3 ZNF652
Basal metabolic rate 3.47 7 4 8.9 0.34 4.5e-01 CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Leg fat percentage (left) 6.54 6 4 8.9 0.95 3.8e-03 FAM108C1 MLLT10 MST1R PMS2P5 RPS6KL1 SH3GL1P3
Arm fat-free mass (left) 3.76 7 2 4.4 0.30 5.2e-01 CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1
Number of operations (self-reported) 4.36 2 0 0.0 0.00 1.0e+00 MLLT10 MST1R
Average weekly beer plus cider intake 2.15 1 1 2.2 0.00 1.0e+00 MST1R
Irritability 1.50 1 0 0.0 0.00 1.0e+00 RPS6KL1
Fractured/broken bones in last 5 years 1.75 1 0 0.0 0.00 1.0e+00 SH3GL1P3
Age started oral contraceptive pill 2.00 2 0 0.0 0.00 1.0e+00 MST1R ZNF652
Diastolic blood pressure, automated reading 11.81 11 7 15.6 0.91 1.2e-04 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 MST1R PMS2P5 SH2B3 TMEM133 ZNF652 ZNF831
Myopia 1.42 1 0 0.0 0.00 1.0e+00 SH3GL1P3
Vascular/heart problems diagnosed by doctor 15.57 12 8 17.8 -0.92 1.7e-05 CGREF1 CISD2 CTC-428G20.3 FAM108C1 FES MLLT10 PMS2P5 PPP2R2D SH2B3 TMEM133 ZNF652 ZNF831
Cholesterol lowering medication 9.19 1 1 2.2 0.00 1.0e+00 SORT1
Pain experienced in last month 4.90 5 1 2.2 -0.65 2.3e-01 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3
Heart attack/myocardial infarction (self-reported) 6.62 4 1 2.2 1.00 5.8e-04 FES SH2B3 SORT1 ZNF652
Heart disease (siblings) 3.01 1 0 0.0 0.00 1.0e+00 FES
Impedance of whole body 4.14 7 4 8.9 -0.81 2.7e-02 CGREF1 CISD2 FAM108C1 MLLT10 MST1R PMS2P5 ZNF652
Leg fat mass (left) 6.49 5 5 11.1 0.98 3.8e-03 FAM108C1 MLLT10 MST1R PMS2P5 SH3GL1P3
Arm predicted mass (left) 3.77 7 2 4.4 0.29 5.2e-01 CGREF1 FAM108C1 MLLT10 MST1R SH2B3 SH3GL1P3 SORT1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 3 0.086 1.9
GTEx Adipose Visceral Omentum 2 0.098 1.9
GTEx Adrenal Gland 3 0.206 1.8
GTEx Artery Aorta 6 0.202 2.0
GTEx Artery Coronary 2 0.169 1.8
GTEx Artery Tibial 7 0.186 1.9
GTEx Brain Caudate basal ganglia 2 0.217 1.8
GTEx Brain Cerebellar Hemisphere 3 0.201 1.9
GTEx Brain Cerebellum 5 0.252 2.1
GTEx Brain Cortex 3 0.290 1.9
GTEx Brain Frontal Cortex BA9 2 0.216 1.9
GTEx Brain Hippocampus 0 0.000 1.9
GTEx Brain Hypothalamus 0 0.000 1.6
GTEx Brain Nucleus accumbens basal ganglia 1 0.116 1.7
GTEx Brain Putamen basal ganglia 1 0.160 1.7
GTEx Breast Mammary Tissue 3 0.152 1.9
GTEx Breast Mammary Tissue (Male) 1 0.084 1.8
GTEx Breast Mammary Tissue (Female) 2 0.122 1.8
GTEx Cells EBV-transformed lymphocytes 1 0.070 1.8
GTEx Cells Transformed fibroblasts 8 0.191 1.9
GTEx Colon Sigmoid 3 0.205 1.9
GTEx Colon Transverse 3 0.145 1.8
GTEx Esophagus Gastroesophageal Junction 3 0.208 1.9
GTEx Esophagus Mucosa 6 0.181 1.9
GTEx Esophagus Muscularis 4 0.124 1.8
GTEx Heart Atrial Appendage 2 0.127 1.9
GTEx Heart Left Ventricle 1 0.065 1.8
GTEx Liver 1 0.139 1.8
GTEx Lung 5 0.174 1.9
GTEx Muscle Skeletal 4 0.138 1.9
GTEx Nerve Tibial 6 0.139 1.8
GTEx Ovary 1 0.110 1.8
GTEx Pancreas 2 0.123 1.9
GTEx Pituitary 1 0.090 1.8
GTEx Prostate 1 0.120 1.9
GTEx Skin Not Sun Exposed Suprapubic 7 0.285 2.0
GTEx Skin Sun Exposed Lower leg 8 0.220 1.9
GTEx Small Intestine Terminal Ileum 2 0.434 2.0
GTEx Spleen 3 0.213 1.8
GTEx Stomach 2 0.138 1.8
GTEx Testis 3 0.095 1.9
GTEx Thyroid 5 0.125 1.8
GTEx Uterus 1 0.176 1.7
GTEx Vagina 1 0.157 1.8
GTEx Whole Blood 2 0.100 1.9
METSIM Adipose 4 0.087 1.8
NTR Blood 3 0.125 1.8
ROSMAP Brain Pre-frontal Cortex 10 0.228 1.8
YFS Blood 3 0.065 1.7
CommonMind Brain Pre-frontal Cortex 8 0.149 1.8
The Cancer Genome Atlas Bladder Urothelial Carcinoma 2 0.121 1.7
The Cancer Genome Atlas Breast Invasive Carcinoma 6 0.136 1.8
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 1 0.091 1.7
The Cancer Genome Atlas Colon Adenocarcinoma 2 0.097 1.7
The Cancer Genome Atlas Esophageal Carcinoma 1 0.146 1.7
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.7
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 4 0.147 1.8
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 5 0.122 1.7
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 2 0.098 1.7
The Cancer Genome Atlas Brain Lower Grade Glioma 5 0.116 1.7
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 2 0.181 1.7
The Cancer Genome Atlas Lung Adenocarcinoma 7 0.238 1.8
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 2 0.080 1.7
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 1 0.063 1.7
The Cancer Genome Atlas Pancreatic Adenocarcinoma 3 0.181 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 1 0.075 1.7
The Cancer Genome Atlas Prostate Adenocarcinoma 5 0.108 1.7
The Cancer Genome Atlas Rectum Adenocarcinoma 0 0.000 1.5
The Cancer Genome Atlas Soft Tissue Sarcoma 1 0.094 1.7
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.9
The Cancer Genome Atlas Stomach Adenocarcinoma 3 0.178 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.7
The Cancer Genome Atlas Thyroid Carcinoma 4 0.078 1.8
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.6